Ondansetron-induced aminotransferase level elevation: Case report and review of the literature

Pharmacotherapy

Volumn 28, Issue 12, 2008, Pages 1542-1546

  Lewandowski, Michael J ^a,c   Chapman, Scott A ^a,b  

^a NORTH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; AST; Nausea; Ondansetron

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DULOXETINE; GEMFIBROZIL; GLYCERYL TRINITRATE; HEPARIN; METOCLOPRAMIDE; MORPHINE; OMEPRAZOLE; ONDANSETRON; TROPONIN I;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CORONARY ARTERY DISEASE; DEPRESSION; DRUG WITHDRAWAL; FAMILIAL HYPERLIPEMIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; LIVER FUNCTION TEST; NAUSEA; SIDE EFFECT;

EID: 57149089874     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.12.1542     Document Type: Article

References (24)

1. Scorza K, Williams A, Philips D, Shaw J. Evaluation of nausea and vomiting. Am Fam Physician 2007;76:76-84.
2. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007;21:813-33.
3. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998;55:173-89.
4. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19:20-5.
5. De Mulder PH, Seynaeve C, Vermoken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;113:834-40.
6. Vermeulen LC, Matuszewski KA, Ratko TA, Butler CD, Burnett DA, Vlasses PH. Evaluation of ondansetron prescribing in U.S. academic medical centers. Arch Intern Med 1994;154:1733-40.
7. GlaxoSmithKline. Zofran (ondansetron) package insert. Philadelphia, PA; 2006.
8. Warden CR, Moreno R, Daya M. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting. Prehosp Emerg Care 2008;12:87-91.
9. Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 1996;354:1698-705.
10. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy undergoing surgery. Am J Health Syst Pharm 1999;56:729-64.
11. Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992;19:53-60.
12. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992;19:26-32.
13. du Bois A, Meerphol HG, Vach W, Kommoss FG, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992;28:450-7.
14. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1993;27:438-41.
15. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969-75.
16. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician 1999;59:2223-32.
17. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007;11:459-75.
18. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30:277-94.
19. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
20. Sledge GW, Einhorn L, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70:2524-8.
21. Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-8.
22. Fraschini G, Ciociola A, Esparza L, et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 1991;9:1268-74.
23. Agura ED, Brown MC, Schaffer R, Donaldson G, Shen DD. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant 1995;16:213-22.
24. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.